• Adverse events and clinical laboratory results [ Time Frame: From first vaccine to 6 weeks after the last ] [ Designated as safety issue: Yes ]
  

• Tumor response as measured using the RECIST criteria [ Time Frame: 18 months after last vaccine ] [ Designated as safety issue: No ]
  

Biological: Melaxin (autologous dendritoma vaccine) and BCG
Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.

Chemotherapy and immunotherapy are the main therapies for metastatic melanoma with the hope of prolonging survival. The ideal immunotherapy would consist of the professional antigen-presenting cell, the dendritic cell, with the entire repertoire of tumor antigens inside. The best way to achieve this is by creating an autologous hybrid fusion cell of the dendritic cell and tumor cell. In this study, melanoma tumor tissue surgically removed from the patient will be disassociated into single cells, irradiated and fused to dendritic cells produced by culturing the patient's blood monocytes. Prior to the electrofusion procedure, the tumor cells are stained red and the dendritic cells are stained green. After fusion, the uniquely colored fused cells, or dendritomas, are separated from the unfused cells by use of a fluorescence activated cell sorter. This highly purified population is then divided into 4 doses containing 250,000 dendritomas each and frozen. Each dose is thawed, diluted to 1 ml with Sterile Saline for Injection containing 5% human serum albumin and administered subcutaneously over a lymph node bed to the patient once every 4 weeks. A separate injection of BCG is administered in the same area within 10 minutes of the dendritoma injection. The safety and efficacy of the therapy will be evaluated in 25 patients.

Inclusion Criteria:

• Ability to give informed consent
• Male or female patient whose age is > 18 years of age
• Histological documented Stage IV malignant melanoma (AJCC sixth edition)
• Pathology report from tumor specimen verifying melanoma diagnosis
• Free of infection
• Hemoglobin> 9.0gm/dL, WBC>3000/mm3, platelets> 100,000mm3
• Liver function test that are less than 2 times the upper limit of normal of the reference range for the testing laboratory
• Adequate cardiac function-any evidence of ischemic heart disease demonstrated by history, physical, or EKG will require referral to a cardiologist for evaluation and clearance prior to protocol therapy
• No immunotherapy within the past 3 months
• A minimum of 4 doses of lot-released, autologus Melaxin (1.0 million dendritomas)

Exclusion Criteria:

• Other malignancies in the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix
• Has received any immunosuppressive agent within 30 days prior to treat
• Creatinine> 2.5mg/dL or currently on dialysis
• Positive serum pregnancy test, breast-feeding,or planning to conceive or father or father a child in the period surrounding the study as described in the informed consent.
• Women of childbearing potential who cannot follow the directions for birth control
• ECOG performance status greater than 3
• Positive Rdonr panel (HIV 1, 2; HTLV 1,2; Hepatitis B and C)
• History of a seizure disorder
• Brain metastases that have progressed within the last 6 months
• No measurable disease